Provided by Tiger Fintech (Singapore) Pte. Ltd.

Reviva Pharmaceuticals Holdings, Inc.

0.3600
-0.0250-6.49%
Post-market: 0.37400.0140+3.89%16:59 EDT
Volume:2.14M
Turnover:800.92K
Market Cap:24.48M
PE:-0.47
High:0.3955
Open:0.3955
Low:0.3600
Close:0.3850
Loading ...

Reviva Pharmaceuticals Q1 EPS $(0.13) Beats $(0.20) Estimate

Benzinga
·
16 May

BRIEF-Reviva Pharmaceuticals Q1 EPS USD -0.13

Reuters
·
16 May

Reviva Pharmaceuticals Q1 Net Income USD -6.4 Million

THOMSON REUTERS
·
16 May

Reviva Pharmaceuticals Q1 EPS USD -0.13

THOMSON REUTERS
·
16 May

Reviva Pharmaceuticals Holdings Inc expected to post a loss of 18 cents a share - Earnings Preview

Reuters
·
09 May

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

TIPRANKS
·
01 May

Reviva to Participate in the Citizens Life Sciences Conference

GlobeNewswire
·
29 Apr

Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital

Dow Jones
·
24 Apr

Reviva Pharmaceuticals Holdings Inc : Benchmark Cuts Target Price to $14 From $17

THOMSON REUTERS
·
09 Apr

RVPH: M&A Deals Highlight Brilaroxazine Value

Zacks Small Cap Research
·
07 Apr

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

TIPRANKS
·
04 Apr

Reviva Pharm Holdings Is Maintained at Buy by D. Boral Capital

Dow Jones
·
01 Apr

BRIEF-Reviva Pharmaceuticals Holdings Files For Non-Timely 10-K - SEC Filing

Reuters
·
01 Apr

Reviva Pharmaceuticals Holdings Files for Non-Timely 10-K - SEC Filing

THOMSON REUTERS
·
01 Apr

Reviva Pharmaceuticals: Expects to Report Material Weaknesses in Internal Control Over Financial Reporting

THOMSON REUTERS
·
01 Apr

BRIEF-Reviva Pharmaceuticals FY EPS USD -0.9

Reuters
·
01 Apr

Reviva Pharmaceuticals FY EPS USD -0.9

THOMSON REUTERS
·
01 Apr

Press Release: Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Dow Jones
·
01 Apr

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
24 Mar

Reviva to Participate in the 2025 BIO CEO & Investor Conference

GlobeNewswire
·
30 Jan